Cleveland Clinic Management of Checkpoint Inhibitor-Related Toxicity 2024

Name: Cleveland Clinic Management of Checkpoint Inhibitor-Related Toxicity 2024 - MeduStudent
SKU: MED-AMB03702
Price: 40.00 USD
Availability: InStock

$40.00

This Product is shared via google drive download link, So please share your correct Gmail id while placing the order .Please note that there are no CME points or certificate associated with this course Samples for Courses Can be found here : Free Samples Here!

Include: 35 videos + 1 pdf, size: 8.1 GB

Cleveland Clinic Management of Checkpoint Inhibitor-Related Toxicity 2024

This item: Cleveland Clinic Management of Checkpoint Inhibitor-Related Toxicity 2024

$40.00

Medmastry 2023

1 × Medmastry 2023

$30.00

The Brigham Update In Hospital Medicine 2022

1 × The Brigham Update In Hospital Medicine 2022

$10.00

ClinicalKey (1-year Subscription, All Subjects, PC only)

1 × ClinicalKey (1-year Subscription, All Subjects, PC only)

$25.00

Fundamentals of HIV Medicine 2021: CME Edition

1 × Fundamentals of HIV Medicine 2021: CME Edition

$10.00

Masterclass In Practical Geriatrics

1 × Masterclass In Practical Geriatrics

$55.00

SKU: MED-AMB03702 Category: Internal Medicine

Description

Cleveland Clinic Management of Checkpoint Inhibitor-Related Toxicity 2024

Include: 35 videos + 1 pdf, size: 8.1 GB

Target Audience: immunologists

Information:

Twelve checkpoint inhibitor therapies have been approved since 2011 in a wide variety of cancers, including tumor-agnostic indications for adult and pediatric patients with unresectable or metastatic, microsatellite instability-high (MSI-H) or mismatch repair deficient cancer.

Immune checkpoint blockade leads to a new spectrum of dysimmune toxicity requiring collaboration between oncologist providers and specialists to improve the understanding of the mechanism, diagnosis, and management of irAEs. Six CAR T-cell therapies have been approved since 2017 for the treatment of blood cancers, including lymphomas, some forms of leukemia, and, most recently, multiple myeloma.

Medical subspecialists, nurses, nurse practitioners, physician assistants, pharmacists, and residents/ fellows are invited to attend.

Learning Objectives

As a result of attending the course, the participant will be able to:

Describe the mechanism of action associated with checkpoint inhibitor therapies and the biologics used in the treatment of immune-related adverse events.
Identify the spectrum of immune-related adverse events that can occur with immune checkpoint inhibitor therapies and CAR T-cell therapies.
Implement assessment criteria, diagnostic testing, and interventions to improve early identification and management of immune-related AEs.
Recognize the importance and necessity of the multidisciplinary approach in treatment of immune-related adverse events.

The Cleveland Clinic Management of Checkpoint Inhibitorrelated Toxicity 2024 is designed for a multidisciplinary audience. This includes medical subspecialists, nurses, nurse practitioners, physician assistants, pharmacists, and residents/fellows. The course aims to improve understanding of the mechanism, diagnosis, and management of immune-related adverse events (irAEs) associated with checkpoint inhibitor therapies and CAR T-cell therapies

Topics:

brochure.pdf
Session 1 Future of irAE Management Abstract 1.mp4
Session 1 Future of irAE Management Abstract 2.mp4
Session 1 Future of irAE Management Challenges of irAE Management in Community Oncology Settings.mp4
Session 1 Future of irAE Management How are Inpatient irAEs Managed at Mass General.mp4
Session 1 Future of irAE Management How are irAEs Managed at Cleveland Clinic.mp4
Session 1 Future of irAE Management How are Outpatient irAEs Managed at Mass General.mp4
Session 1 Future of irAE Management Introduction Where are we now with irAE Management.mp4
Session 1 Future of irAE Management Panel Discussion Q&A.mp4
Session 1 Future of irAE Management Pharmacology of Steroids.mp4
Session 1 Future of irAE Management Q&A 1.mp4
Session 1 Future of irAE Management Q&A 2.mp4
Session 1 Future of irAE Management Refractory Therapies.mp4
Session 1 Future of irAE Management Wrap Up Adjourn Reception & Posters.mp4
SESSION 1 MANAGEMENT OF COMMON Dermatologic irAEs.mp4
SESSION 1 MANAGEMENT OF COMMON Endocrine irAEs.mp4
SESSION 1 MANAGEMENT OF COMMON irAEs Case Presentations Panel Discussion Q&A.mp4
SESSION 1 MANAGEMENT OF COMMON Pulmonary irAEs.mp4
SESSION 1 MANAGEMENT OF COMMON Rheumatologic irAEs.mp4
SESSION 2 KEYNOTE ADDRESS.mp4
SESSION 3 GUTSY FEELINGS Case Presentations Panel Discussion Q&A.mp4
SESSION 3 GUTSY FEELINGS Gastrointestinal irAEs.mp4
SESSION 3 GUTSY FEELINGS Hepatologic irAEs.mp4
SESSION 3 GUTSY FEELINGS Introduction.mp4
SESSION 4 SPEED ROUNDS RECOGNITION OF UNDERAPPRECIATED Infectious Disease.mp4
SESSION 4 SPEED ROUNDS RECOGNITION OF UNDERAPPRECIATED Introduction.mp4
SESSION 4 SPEED ROUNDS RECOGNITION OF UNDERAPPRECIATED irAEs Case Presentations Panel Discussion Q&A.mp4
SESSION 4 SPEED ROUNDS RECOGNITION OF UNDERAPPRECIATED Nephrologic irAEs.mp4
SESSION 4 SPEED ROUNDS RECOGNITION OF UNDERAPPRECIATED Neurologic.mp4
SESSION 4 SPEED ROUNDS RECOGNITION OF UNDERAPPRECIATED Ophthalmologic irAEs.mp4
SESSION 5 HEME CAR T-cell and TIL Therapies.mp4
SESSION 5 HEME Case Presentations Panel Discussion Q&A.mp4
SESSION 5 HEME Hematologic irAEs.mp4
SESSION 5 HEME Introduction.mp4
SESSION 5 HEME Wrap Up Adjourn.mp4
Welcome Introduction.mp4